
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.72 | -10.9589041096 | 6.57 | 6.66 | 5.84 | 1174257 | 6.30114563 | CS |
4 | -0.34 | -5.49273021002 | 6.19 | 7.17 | 5.48 | 1276048 | 6.25952777 | CS |
12 | -1.29 | -18.0672268908 | 7.14 | 7.22 | 5.41 | 1305043 | 6.13399895 | CS |
26 | -3.07 | -34.4170403587 | 8.92 | 9.17 | 5.41 | 1411315 | 7.19737972 | CS |
52 | -13.78 | -70.1986754967 | 19.63 | 23.48 | 5.41 | 1249862 | 10.54980393 | CS |
156 | -8.36 | -58.8318085855 | 14.21 | 24.17 | 5.41 | 1018484 | 13.01267863 | CS |
260 | -12.77 | -68.58216971 | 18.62 | 42.82 | 5.41 | 889660 | 15.97576659 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions